- The stock price of Biogen (NASDAQ: BIIB) fell by over 1.7% during intraday trading today. This is why it happened.
The stock price of Biogen (NASDAQ: BIIB) fell by over 1.7% during intraday trading today. Investors are responding negatively to the company’s fourth-quarter results.
Biogen reported Q4 EPS of $3.39, which is about $0.01 lower than analyst estimates of $3.40. And the revenue for the quarter was $2.73 billion compared to a consensus estimate of $2.62 billion.
In terms of guidance, Biogen expects FY2022 EPS of $14.25-$16.00 compared to a consensus of $19.18. And Biogen expects FY2022 revenue of $9.7 billion-10 billion compared to a consensus of $10.87 billion.
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.